Ro 8-4304 hydrochlorideCAS# 1312991-77-7 |
2D Structure
- BS-181
Catalog No.:BCC1439
CAS No.:1092443-52-1
- WHI-P180 hydrochloride
Catalog No.:BCC4243
CAS No.:153437-55-9
- SNS-032 (BMS-387032)
Catalog No.:BCC1152
CAS No.:345627-80-7
- Dinaciclib (SCH727965)
Catalog No.:BCC3765
CAS No.:779353-01-4
- RGB-286638
Catalog No.:BCC5519
CAS No.:784210-87-3
- AT7519 Hydrochloride
Catalog No.:BCC1376
CAS No.:902135-91-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1312991-77-7 | SDF | Download SDF |
PubChem ID | 11957680 | Appearance | Powder |
Formula | C21H24ClFN2O3 | M.Wt | 406.88 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 10 mM in water and to 100 mM in DMSO | ||
Chemical Name | 4-[3-[4-(4-fluorophenyl)-3,6-dihydro-2H-pyridin-1-yl]-2-hydroxypropoxy]benzamide;hydrochloride | ||
SMILES | C1CN(CC=C1C2=CC=C(C=C2)F)CC(COC3=CC=C(C=C3)C(=O)N)O.Cl | ||
Standard InChIKey | MQOXWHKUQOFFJW-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C21H23FN2O3.ClH/c22-18-5-1-15(2-6-18)16-9-11-24(12-10-16)13-19(25)14-27-20-7-3-17(4-8-20)21(23)26;/h1-9,19,25H,10-14H2,(H2,23,26);1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | NMDA receptor antagonist (IC50 = 0.4 μM) that displays > 100 fold selectivity for NR2B-containing receptors over NR2A-containing receptors. Exhibits an activity-dependent mechanism of NMDA antagonism and is competitive with respect to spermine . |
Ro 8-4304 hydrochloride Dilution Calculator
Ro 8-4304 hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.4577 mL | 12.2886 mL | 24.5773 mL | 49.1545 mL | 61.4432 mL |
5 mM | 0.4915 mL | 2.4577 mL | 4.9155 mL | 9.8309 mL | 12.2886 mL |
10 mM | 0.2458 mL | 1.2289 mL | 2.4577 mL | 4.9155 mL | 6.1443 mL |
50 mM | 0.0492 mL | 0.2458 mL | 0.4915 mL | 0.9831 mL | 1.2289 mL |
100 mM | 0.0246 mL | 0.1229 mL | 0.2458 mL | 0.4915 mL | 0.6144 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Ro 25-6981 Maleate
Catalog No.:BCC4159
CAS No.:1312991-76-6
- Scutebarbatine Z
Catalog No.:BCN6991
CAS No.:1312716-28-1
- Scutebarbatine Y
Catalog No.:BCN6994
CAS No.:1312716-27-0
- Scutebarbatine X
Catalog No.:BCN6997
CAS No.:1312716-26-9
- Scutebarbatine W
Catalog No.:BCN7011
CAS No.:1312716-25-8
- Antibiotic PF 1018
Catalog No.:BCN2149
CAS No.:131256-42-3
- PF 5081090
Catalog No.:BCC6148
CAS No.:1312473-63-4
- Cornuside
Catalog No.:BCN5007
CAS No.:131189-57-6
- NSC 624206
Catalog No.:BCC7988
CAS No.:13116-77-3
- Sodium Demethylcantharidate
Catalog No.:BCN8394
CAS No.:13114-29-9
- mGlu2 agonist
Catalog No.:BCC1745
CAS No.:1311385-32-6
- BIX 02565
Catalog No.:BCC4303
CAS No.:1311367-27-7
- threo Ifenprodil hemitartrate
Catalog No.:BCC7508
CAS No.:1312991-83-5
- Nystose
Catalog No.:BCN5397
CAS No.:13133-07-8
- NVP-CGM097
Catalog No.:BCC5395
CAS No.:1313363-54-0
- erythro-Guaiacylglycerol beta-threo-syringylglycerol ether
Catalog No.:BCN7333
CAS No.:1313434-74-0
- Periplocin
Catalog No.:BCN2655
CAS No.:13137-64-9
- Teijin compound 1
Catalog No.:BCC6057
CAS No.:1313730-14-1
- Boc-Trp-OH
Catalog No.:BCC3455
CAS No.:13139-14-5
- Boc-Leu-OH.H2O
Catalog No.:BCC3408
CAS No.:13139-15-6
- Boc-Ile-OH.1/2H2O
Catalog No.:BCC3406
CAS No.:13139-16-7
- CBZ-Osu
Catalog No.:BCC2798
CAS No.:13139-17-8
- Hemopressin (human, mouse)
Catalog No.:BCC6065
CAS No.:1314035-51-2
- TC-N 22A
Catalog No.:BCC6150
CAS No.:1314140-00-5
State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist.[Pubmed:9504387]
Br J Pharmacol. 1998 Feb;123(3):463-72.
1. Subunit-selective blockade of N-methyl-D-aspartate (NMDA) receptors provides a potentially attractive strategy for neuroprotection in the absence of undesirable side effects. Here, we describe a novel NR2B-selective NMDA antagonist, 4- inverted question mark3-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-2-hydroxy-propoxy inverted question mark-benzamide (Ro 8-4304), which exhibits >100 fold higher affinity for recombinant NR1(001)/NR2B than NR1(001)/NR2A receptors. 2. Ro 8-4304 is a voltage-independent, non-competitive antagonist of NMDA receptors in rat cultured cortical neurones and exhibits a state-dependent mode of action similar to that described for ifenprodil. 3. The apparent affinity of Ro 8-4304 for the NMDA receptor increased in an NMDA concentration-dependent manner so that Ro 8-4304 inhibited 10 and 100 microM NMDA responses with IC50s of 2.3 and 0.36 microM, respectively. Currents elicited by 1 microM NMDA were slightly potentiated in the presence of 10 microM Ro 8-4304, and Ro 8-4304 binding slowed the rate of glutamate dissociation from NMDA receptors. 4. These results were predicted by a reaction scheme in which Ro 8-4304 exhibits a 14 and 23 fold higher affinity for the activated and desensitized states of the NMDA receptor, respectively, relative to the agonist-unbound resting state. Additionally, Ro 8-4304 binding resulted in a 3 4 fold increase in receptor affinity for glutamate site agonists. 5. Surprisingly, whilst exhibiting a similar affinity for NR2B-containing NMDA receptors as ifenprodil, Ro 8-4304 exhibited markedly faster kinetics of binding and unbinding to the NMDA receptor. This spectrum of kinetic behaviour reveals a further important feature of this emerging class of NR2B-selective compounds.
An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones.[Pubmed:9729614]
J Physiol. 1998 Oct 1;512 ( Pt 1):17-28.
1. The atypical NR2B subunit-selective NMDA receptor antagonist ifenprodil was originally believed to act as a competitive antagonist at the polyamine binding site of the NMDA receptor. However, a number of studies have suggested that ifenprodil might bind to a distinct site. 2. Using whole-cell voltage clamp recordings, we have studied the interaction of spermine with both ifenprodil and the related NR2B selective antagonist Ro 8-4304 at the NMDA receptor in rat cultured cortical neurones in the presence of saturating concentrations of glycine. 3. Ifenprodil and Ro 8-4304 inhibited steady-state currents evoked by 100 microM NMDA in the absence of spermine with IC50 values of 0.3 and 0.6 microM, respectively. In the presence of 1 and 3 mM spermine, IC50 values for ifenprodil were 1.4 and 1.8 microM and for Ro 8-4304 they were 3. 0 and 7.5 microM, respectively. 4. In the presence of spermine, the on-time constant of receptor blockade by both antagonists was significantly slower than control and the off-time constant of recovery from receptor blockade following removal of Ro 8-4304 was significantly faster. 5. Fast application of spermine during an NMDA steady-state current in the continuous presence of a subsaturating concentration of either antagonist resulted in a biphasic increase in the current, consistent with a fast increase upon spermine binding and a slow increase resultant from dissociation of antagonist due to spermine binding-induced allosteric reduction in receptor antagonist affinity. In agreement with this, at higher, saturating concentrations of antagonist, the slow increase in current amplitude was markedly reduced or absent. 6. These observations are consistent with a non-competitive, allosteric interaction between spermine and the antagonists, such that spermine binding to the NMDA receptor results in a reduction in receptor affinity for the antagonists and vice versa. 7. The effects of Mg2+ on the NMDA-evoked currents and its interaction with ifenprodil were similar to those of spermine, supporting the suggestion that Mg2+ might be the physiological ligand acting at the spermine site mediating glycine-independent stimulation.